Skip to main content
MLTX
NASDAQ Life Sciences

MoonLake's Psoriatic Arthritis Drug Hits Endpoints, But Stock Drops 6%

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$17.105
Mkt Cap
$1.439B
52W Low
$5.95
52W High
$62.75
52W Position info
187% above low
Off High info
73% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

MLTX has more than doubled off its 52-week low of $5.95 on elevated volume (2.4× avg).

Summary

Sonelokimab met all primary and secondary endpoints in the Phase 3 IZAR-1 trial for psoriatic arthritis, with a 42.1% ACR50 response. Despite the positive data, shares fell over 6%, suggesting the market may have expected even stronger results or is concerned about competitive positioning. This follows the earlier Dow Jones report of the trial success, but the sell-off is a new development. The company ended Q2 with $537 million in cash, funding operations into mid-2028. Full 52-week data is expected in H1 2027, and the companion IZAR-2 trial in TNF-refractory patients is enrolling with completion expected in Q3 2026.

At the time of this announcement, MLTX was trading at $17.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.07 info
Change: -$0.530 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.07 info
Change: -$0.550 (-5%) info
Market Cap: $942.131M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.07 info
Change: -$0.540 (-5%) info
Market Cap: $942.131M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.07 info
Change: -$0.7407 (-6%) info
Market Cap: $942.131M info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $11.07 info
Change: -$5.12 (-32%) info
Market Cap: $942.131M info